Late-stage biopharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR) announced on Tuesday its financial results for the fiscal year ended 30 September 2025.

Citius Pharma did not report revenues for the year. The company raised approximately USD61m in gross proceeds from capital raises.

R&D expenses for the year were USD9.2m, compared to USD11.9m in the year-ago period, with G&A expenses of USD18.5m, compared to USD18.2m in the prior year.

The company reported a net loss of USD39.7m or USD3.38 per share, versus a net loss of USD40.2m or USD5.97 per share in the year to 30 September 2024.

Cash and cash equivalents amounted to USD4.3m as of 30 September 2025.

"2025 was a pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018," commented Leonard Mazur, chairman and CEO of Citius Pharma.

"This milestone reflects our ability to execute and our commitment to delivering impactful treatments for patients with limited options.

"With LYMPHIR commercially available as of December 2025, we are focused on its successful launch and adoption in 2026, with even greater opportunities ahead to drive value for patients and shareholders."

Mazur added that the company is actively engaging with the FDA to advance Mino-Lok, exploring additional indications and markets for LYMPHIR, and working to strengthen its financial and operational foundation to support sustained growth.